The canonical clinical features of neuromyelitis optica have been supplemented by other characteristic syndromes and the finding of pathogenic AQP4-IgG autoantibodies. The expanded disease spectrum, NMOSD, is treated with drugs that target the steps in pathogenesis. Promising approaches to predicting and preventing relapses, enhancing recovery from relapse, and achieving immune tolerance are under investigation.
ASJC Scopus subject areas
- General Medicine